

RIGHTS COMMENCE TRADING

5 March 2020

On 2 March 2020, **Surface chemistry and coating Company AnteoTech Limited (ASX: ADO) (“AnteoTech” or “the Company”)** announced a \$3.2 million Renounceable Rights Issue to fund the growth and development of the Battery and Life Sciences divisions. The issue is partially underwritten to \$1.5 million by Mahe Capital Pty Ltd, and sub-underwritten by Chairman Dr Jack Hamilton and Director Mr Chris Parker for \$140,000.

The Company confirm that the rights the subject of the Company’s Renounceable Rights Issue have commenced trading under the ASX code ADORB.

The Rights Issue is open to all eligible shareholders who have a registered address within Australia or New Zealand, and who hold Shares on the Record Date. The Rights Issue will close on 24 March 2020 (unless extended), and eligible shareholders can apply for shortfall in excess of their entitlement.

A prospectus in relation to the Rights Issue was lodged with ASIC on 2 March 2020 and, together with a personalised entitlement acceptance form, will be sent to eligible shareholders shortly.

Eligible shareholders should consider the prospectus in deciding whether to acquire securities under the Rights Issue and will need to complete the personalised entitlement and acceptance form that will accompany the prospectus. The following are indicative dates in respect of the capital raising:

Event	Date
Rights Issue announced	2 March 2020
Ex entitlement date	4 March 2020
Rights trading commences on a deferred settlement basis [ASX code: ADORB]	
Record Date for determining entitlements (5:00pm EST)	5 March 2020
Prospectus and personalised Entitlement and Acceptance Forms sent out to Eligible Shareholders	9 March 2020
Rights trading ends	17 March 2020
Closing date of entitlement issue (5:00pm EST)	24 March 2020
ASX notified of under subscriptions	27 March 2020
Issue date.	31 March 2020

These dates are indicative only and may change, subject to the Corporations Act and Listing Rules.

This announcement is authorised by AnteoTech’s board of directors.

ABOUT ANTEO GROUP – AnteoTech Limited (ADO:ASX)

AnteoTech (formerly Anteo Diagnostics Ltd) is a surface chemistry company with Intellectual Property (“IP”) in its core technology product groups AnteoCoat™, AnteoBind™ and AnteoRelease™. The Company’s purpose is to create shareholder value by identifying and solving important global industry problems by providing unique value-add solutions for its customers. Customers operate in the life sciences, diagnostics, energy and medical devices markets.

For more information, please contact:

Derek Thomson, Chief Executive Officer, Anteo Diagnostics Limited: +61 7 3219 0085

Ben Jarvis, Six Degrees Investor Relations: +61 (0) 413 150 448

Follow AnteoTech on Twitter: <https://twitter.com/AnteoDX> or visit www.anteotech.com

AnteoTech Ltd ACN 070 028 625

Unit 4, 26 Brandl St, Eight Mile Plains, QLD 4113,

Australia **p:** +61 7 3219 0085 **f:** +61 7 3219 0553

contact@anteotech.com www.anteotech.com

For personal use only